BioSpace News Archive

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.

BioAtla, Inc. announced that Scott Smith, President and Sheri Lydick, Senior Vice President, Commercial Strategy will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 15-17, 2022.

Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2022 and provided an update on recent business progress.

Tempest Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

Artelo Biosciences, Inc. today reported financial and operating results for the three months ended September 30, 2022.

ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), and Dana-Farber Cancer Institute have entered into a two-year collaborative agreement to further the research and development of a small molecule, Linebacker-1 (LB-1), that is intended as a therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments.

IceCure Medical Ltd. announced the Centers for Medicare & Medicaid Services assigned its ProSense breast cancer cryoablation procedures with CPT Category III code 0581T to ambulatory payment classification 5091, Level 1 Breast/Lymphatic Surgery and Related Procedures.

Novavax, Inc. today announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company’s BA.1 vaccine candidate (NVX-CoV2515) met the primary strain-change endpoint.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that it will present two posters at the SFN 2022 Neuroscience Annual Meeting, taking place November 12-16, 2022, in San Diego, CA.